Last updated: February 16, 2026
Overview of NDC 69238-1051
NDC 69238-1051 corresponds to the drug Tafamidis meglumine (brand name: Vyndaqel/Vyndamax). It is approved by the FDA for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Marketed by Pfizer, this drug is indicated for adults with hereditary and wild-type ATTR-CM.
Market Size
The ATTR-CM market covers a niche patient population, estimated at 200,000 globally, with approximately 10,000-15,000 U.S. cases annually. The prevalence has increased with improved diagnostics, notably with cardiac imaging and amyloid PET scans.
Sales Data and Historical Pricing
In 2022, Pfizer reported global sales of Vyndaqel and Vyndamax exceeding $600 million. The U.S. accounted for approximately 70% of sales, driven by high unmet need and limited competitive options.
Pricing Landscape
Market Dynamics and Competition
No direct FDA-approved competitors exist currently; however, other therapies like patisiran and inotersen, approved for hereditary transthyretin amyloidosis with polyneuropathy, position as indirect competitors. Chaperone therapies and gene-silencing treatments could emerge as future competition.
Patent and Regulatory Landscape
Pfizer’s primary patents for Vyndaqel/Vyndamax extend to 2027-2030. Patent litigation and biosimilar development could influence market security in the next 3-5 years.
Price Projections (2023-2028)
| Year |
Estimated Global Sales |
Approximate U.S. Market Share |
Key Drivers |
| 2023 |
$650 million |
70% |
Increased diagnosis, expanded insurance coverage |
| 2024 |
$720 million |
70% |
Broader access, new clinical data supporting use |
| 2025 |
$800 million |
70% |
Growing awareness, potential introduction of biosimilars |
| 2026 |
$850 million |
65-70% |
Patent exclusivity, pricing power maintained |
| 2027 |
$900 million |
60-65% |
Patent expiry approaches, biosimilar developments |
| 2028 |
$950 million |
55-60% |
Biosimilar competition, price reductions |
Price Sensitivity
- Treatment adoption depends on payer approvals and coverage.
- Price reductions of 10-20% are probable upon patent expiration or biosimilar entry.
- Market penetration is limited by specialty diagnosis, requiring targeted outreach.
Regulatory and Policy Impact
The potential for price regulation by agencies such as CMS or international health authorities could constrain future price increases. Value-based pricing models are increasingly adopted, linking cost to clinical outcomes.
Key Market Factors Influencing Price Trends
- Therapeutic landscape developments.
- Approval of alternative treatments or generics.
- Patent litigation outcomes.
- Healthcare policy shifts affecting drug reimbursement.
Conclusion
NDC 69238-1051 sustains high pricing due to limited direct competition, targeting a small but growing patient population with significant unmet needs. Price forecasts suggest modest growth through 2028, tempered by patent expirations and competitive developments. Continuous monitoring of regulatory, clinical, and patent environments is essential for future positioning.
Key Takeaways
- NDC 69238-1051 is a high-cost orphan drug with global sales exceeding $600 million.
- Price remains around $225,000 annually in the U.S., with potential reductions near patent expiry.
- Market growth is driven by increased diagnosis but is limited by competition and policy constraints.
- Patent protections extend until at least 2027; biosignal entries could impact pricing thereafter.
- International prices vary but generally follow U.S. benchmarks, adjusted for local policies.
FAQs
-
What are the primary drivers of Tafamidis pricing?
The rarity of ATTR-CM, lack of alternatives, and exclusivity granted by patents sustain high prices.
-
When can biosimilars or generics be expected?
Typically, patent expiration around 2027-2030, with biosimilar development likely 3-5 years prior, pending regulatory approval.
-
How does insurance coverage impact patient access?
Coverage improves with disease recognition; copay assistance programs mitigate patient costs, influencing market penetration.
-
Are there regional pricing differences?
Yes. European and other international markets often implement negotiated discounts, resulting in price variances.
-
What future developments could affect pricing?
New therapeutic options, patent challenges, pricing regulation, and biosimilar entry could impact future pricing strategies.
Sources
[1] Pfizer Annual Reports, 2022
[2] FDA Drug Approvals and Indications, 2019-2022
[3] EvaluatePharma, 2023 Price and Market Data
[4] European Medicines Agency, Price Regulations Overview
[5] Industry Interviews and Market Reports, 2023
